Published in AIDS Weekly, July 26th, 2004
The company has shipped the total amount of vials of Ampligen, required for the trial, to Esteve.
In March 2002, Hemispherx S.A., a subsidiary of Hemispherx Biopharma, entered into a sales and distribution agreement with Esteve. Pursuant to the terms of the agreement, Esteve was granted the exclusive right to market Ampligen in Spain, Portugal, and Andorra for the treatment of chronic fatigue syndrome.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.